Συστατικά

*Συνιστώμενη Ημερήσια Ποσότητα (ΣΗΠ)

Συστατικά: Κιτρικά άλατα μαγνησίου, μικροκρυσταλλική κυτταρίνη, στεατικό μαγνήσιο, διοξείδιο του πυριτίου.

Δεν περιέχει χρωστικές ουσίες, συντηρητικά, γλυκαντικές ουσίες, αλλεργιογόνα σίτου, καλαμποκιού, σόγιας και γάλακτος.

Όλα τα προϊόντα της HEALTH SIGN παράγονται σε Οίκους του Ηνωμένου Βασιλείου και της Ελλάδας, βάσει των αυστηρότατων πρωτοκόλλων της Ευρωπαϊκής Ένωσης γνωστών ως GMP (Good Manufacturing Practice).

Προκειμένου να διασφαλιστεί η ποιότητα των προϊόντων μας, προβαίνουμε σε όλους τους απαραίτητους ελέγχους, από την επιλογή των πρώτων υλών μέχρι και την παραγωγή και φύλαξη των τελικών προϊόντων.

‘Oλα τα προϊόντα μας είναι γνωστοποιημένα στον Ε.Ο.Φ. και διατίθενται σε φαρμακεία.

Οδηγίες χρήσης & Δοσολογία

Λαμβάνετε 4 κάψουλες ημερησίως ή σύμφωνα με τις οδηγίες του γιατρού σας. Να μην υπερβαίνετε την συνιστώμενη ημερήσια δόση.

Οδηγίες για τη φύλαξη του προϊόντος: Το προϊόν διατηρείται σε δροσερό και ξηρό μέρος. Φυλάσσεται μακριά από μικρά παιδιά.

Τα συμπληρώματα διατροφής δεν πρέπει να χρησιμοποιούνται ως υποκατάστατο μιας ισορροπημένης δίαιτας. Συμβουλευτείτε τον γιατρό σας πριν καταναλώσετε το προϊόν εάν είσθε έγκυος ή θηλάζετε.

Αρ. Πρωτ. Γνωστ. ΕΟΦ

72931/23-9-2013

Ο Αριθμός Γνωστοποίησης δεν επέχει θέση άδειας κυκλοφορίας από τον ΕΟΦ.

Βιβλιογραφία

1. Rude RK, Singer FR, Gruber HE. Skeletal and hormonal effects of magnesium deficiency. J Am Coll Nutr. Apr 2009;28(2):131-141.

2. Hartwig A. Role of magnesium in genomic stability. Mutat Res. Apr 18 2001;475(1-2):113-121.

3. Tong GM, Rude RK. Magnesium deficiency in critical illness. J Intensive Care Med. Jan-Feb 2005;20(1):3-17.

4. Chacko SA, Song Y, Nathan L, et al. Relations of dietary magnesium intake to biomarkers of inflammation and endothelial dysfunction in an ethnically diverse cohort of postmenopausal women. Diabetes Care. Feb 2010;33(2):304-310.

5. Zhang W, Iso H, Ohira T, et al. Associations of dietary magnesium intake with mortality from cardiovascular disease: the JACC study. Atherosclerosis. Apr 2012;221(2):587-595.

6. Chiuve SE, Korngold EC, Januzzi JL, Jr., et al. Plasma and dietary magnesium and risk of sudden cardiac death in women. Am J Clin Nutr. Feb 2011;93(2):253-260.

7. Peacock JM, Ohira T, Post W, et al. Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. Sep 2010;160(3):464-470.

8. Larsson SC, Orsini N, Wolk A. Dietary magnesium intake and risk of stroke: a meta-analysis of prospective studies. Am J Clin Nutr. Feb 2012;95(2):362-366.

9. McKeown NM, Jacques PF, Zhang XL, et al. Dietary magnesium intake is related to metabolic syndrome in older Americans. Eur J Nutr. Jun 2008;47(4):210-216.

10. He K, Liu K, Daviglus ML, et al. Magnesium intake and incidence of metabolic syndrome among young adults. Circulation. Apr 4 2006;113(13):1675-1682.

11. Dong JY, Xun P, He K, et al. Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies. Diabetes Care. Sep 2011;34(9):2116-2122.

12. Huerta MG, Roemmich JN, Kington ML, et al. Magnesium deficiency is associated with insulin resistance in obese children. Diabetes Care. May 2005;28(5):1175-1181.

13. Kazaks AG, Uriu-Adams JY, Albertson TE, et al. Effect of oral magnesium supplementation on measures of airway resistance and subjective assessment of asthma control and quality of life in men and women with mild to moderate asthma: a randomized placebo controlled trial. J Asthma. Feb 2010;47(1):83-92.

14. Forsyth AK, Williams PG, Deane FP. Nutrition status of primary care patients with depression and anxiety. Aust J Prim Health. 2012;18(2):172-176.

15. Derom ML, Martinez-Gonzalez MA, Sayon-Orea Mdel C, et al. Magnesium intake is not related to depression risk in Spanish university graduates. J Nutr. Jun 2012;142(6):1053-1059.

16. Li K, Kaaks R, Linseisen J, et al. Dietary calcium and magnesium intake in relation to cancer incidence and mortality in a German prospective cohort (EPIC-Heidelberg). Cancer Causes Control. Oct 2011;22(10):1375-1382.

17. Molina-Montes E, Wark PA, Sanchez MJ, et al. Dietary intake of iron, heme-iron and magnesium and pancreatic cancer risk in the European prospective investigation into cancer and nutrition cohort. Int J Cancer. Oct 1 2012;131(7):E1134-1147.

18. Wark PA, Lau R, Norat T, et al. Magnesium intake and colorectal tumor risk: a case-control study and meta-analysis. Am J Clin Nutr. Aug 1 2012.

19. Mahabir S, Wei Q, Barrera SL, et al. Dietary magnesium and DNA repair capacity as risk factors for lung cancer. Carcinogenesis. May 2008;29(5):949-956.

20. Stepura OB, Martynow AI. Magnesium orotate in severe congestive heart failure (MACH). Int J Cardiol. May 1 2009;134(1):145-147.

21. Almoznino-Sarafian D, Sarafian G, Berman S, et al. Magnesium administration may improve heart rate variability in patients with heart failure. Nutr Metab Cardiovasc Dis. Nov 2009;19(9):641-645.

22. Mooren FC, Kruger K, Volker K, et al. Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects – a double-blind, placebo-controlled, randomized trial. Diabetes Obes Metab. Mar 2011;13(3):281-284.

23. Chacko SA, Sul J, Song Y, et al. Magnesium supplementation, metabolic and inflammatory markers, and global genomic and proteomic profiling: a randomized, double-blind, controlled, crossover trial in overweight individuals. Am J Clin Nutr. Feb 2011;93(2):463-473.

24. Kass L, Weekes J, Carpenter L. Effect of magnesium supplementation on blood pressure: a meta-analysis. Eur J Clin Nutr. Apr 2012;66(4):411-418.

25. Hatzistavri LS, Sarafidis PA, Georgianos PI, et al. Oral magnesium supplementation reduces ambulatory blood pressure in patients with mild hypertension. Am J Hypertens. Oct 2009;22(10):1070-1075.

26. Dickinson HO, Nicolson DJ, Campbell F, et al. Magnesium supplementation for the management of essential hypertension in adults. Cochrane Database Syst Rev. 2006(3):CD004640.

27. Khan AM, Sullivan L, McCabe E, et al. Lack of association between serum magnesium and the risks of hypertension and cardiovascular disease. Am Heart J. Oct 2010;160(4):715-720.

28. Carpenter TO, DeLucia MC, Zhang JH, et al. A randomized controlled study of effects of dietary magnesium oxide supplementation on bone mineral content in healthy girls. J Clin Endocrinol Metab. Dec 2006;91(12):4866-4872.

29. Aydin H, Deyneli O, Yavuz D, et al. Short-term oral magnesium supplementation suppresses bone turnover in postmenopausal osteoporotic women. Biol Trace Elem Res. Feb 2010;133(2):136-143.

30. Gontijo-Amaral C, Guimaraes EV, Camargos P. Oral magnesium supplementation in children with cystic fibrosis improves clinical and functional variables: a double-blind, randomized, placebo-controlled crossover trial. Am J Clin Nutr. Jul 2012;96(1):50-56.

31. Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. Jun 2012;52(6):930-945.

32. Whelan AM, Jurgens TM, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol. Fall 2009;16(3):e407-429.

33. Park H, Parker GL, Boardman CH, et al. A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients. Support Care Cancer. Jun 2011;19(6):859-863.

34. Young GL, Jewell D. Interventions for leg cramps in pregnancy. Cochrane Database Syst Rev. 2002(1):CD000121.

35. Fox CH, Mahoney MC, Ramsoomair D, et al. Magnesium deficiency in African-Americans: does it contribute to increased cardiovascular risk factors? J Natl Med Assoc. Apr 2003;95(4):257-262.

36. Sanchez-Fructuoso AI, Santin Cantero JM, Perez Flores I, et al. Changes in magnesium and potassium homeostasis after conversion from a calcineurin inhibitor regimen to an mTOR inhibitor-based regimen. Transplant Proc. Oct 2010;42(8):3047-3049.

37. Muller MP, Dresser L, Raboud J, et al. Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. Pharmacotherapy. Apr 2007;27(4):494-503.

38. Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM. Jun 2010;103(6):387-395.

39. Hodgkinson E, Neville-Webbe HL, Coleman RE. Magnesium depletion in patients receiving cisplatin-based chemotherapy. Clin Oncol (R Coll Radiol). Nov 2006;18(9):710-718.

40. Petrelli F, Borgonovo K, Cabiddu M, et al. Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf. May 2012;11 Suppl 1:S9-19.

41. Dalcanale L, Oliveira CP, Faintuch J, et al. Long-term nutritional outcome after gastric bypass. Obes Surg. Feb 2010;20(2):181-187.

42. Van Laecke S, Desideri F, Geerts A, et al. Hypomagnesemia and the risk of new-onset diabetes after liver transplantation. Liver Transpl. Nov 2010;16(11):1278-1287.

43. Swaminathan R. Magnesium metabolism and its disorders. Clin Biochem Rev. May 2003;24(2):47-66.

44. Weng YM, Chen SY, Chen HC, et al. Hypermagnesemia in a Constipated Female. J Emerg Med. Jan 13 2012.